The EU Commission sends statements of objections to two pharmaceutical companies over a possible delayed entry of a generic pain-killer (Johnson & Johnson / Novartis)

L'Ecluse, Peter

Previous article The UK OFT issues statement of objections to certain pharmaceutical companies alleging they acted to delay effective competition in the UK supply of medicine (GSK / GUK / Alpharma / IVAX) Next article The US FTC releases a summary of its new report on pharma patent litigation finding an increase in reverse payment settlements based on an expanded definition of payments

31 Jan 2013

The EU Commission sends statements of objections to two pharmaceutical companies over a possible delayed entry of a generic pain-killer (Johnson & Johnson / Novartis)

KEYWORDS

Reference

EU Commission, Johnson & Johnson / Novartis, Press release, IP/13/81, 31 January 2013,

On 31 January 2013, the European Commission announced that it had sent a Statement of Objections (“SO”) to pharmaceutical companies Johnson & Johnson (“J&J”) and Novartis over suspicions that

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Peter L’Ecluse
Van Bael & Bellis (Brussels)

Belgium 142 contributions 49253 visits

Quotation

Peter L'Ecluse, The EU Commission sends statements of objections to two pharmaceutical companies over a possible delayed entry of a generic pain-killer (Johnson & Johnson / Novartis), 31 January 2013, e-Competitions Pay-for-delay agreements, Art. N° 58203

Visites 251